Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 12:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 7,057 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Cancer, Breast Neoplasms Clear all
Completed Not applicable Interventional

Geriatric Assessment and Promotores (GAP) Pilot Feasibility Study

NCT06125145
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Prostate Cancer
Interventions
Geriatric Assessment and Promotora Coaching
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
65 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 23, 2026, 12:57 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Increasing Breast and Colorectal Cancer Screening in the Community

NCT07748377
View directory record Official record
Conditions
Colorectal Neoplasms, Breast Neoplasms
Interventions
Chi gung: Stay Well, Live Well
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
45 Years to 75 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
7
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 23, 2026, 12:57 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Contrast-enhanced Spectral Mammography (CESM) Breast Cancer Screening

NCT04904757
View directory record Official record
Conditions
Mammographic Breast Density, Mammography
Interventions
Contrast-enhanced spectral mammography (CESM)
Device
Lead sponsor
University of Virginia
Other
Eligibility
40 Years to 69 Years · Female only
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Oct 23, 2026, 12:57 PM EDT
Completed No phase listed Observational

Use of Dynamic Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor-Associated Vasculature in Patients With Metastatic Breast Cancer

NCT00071357
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 12:57 PM EDT
Active, not recruiting No phase listed Observational

Endocrine Therapy-Induced Alopecia in Postmenopausal and Premenopausal Female Breast Cancer Patients

NCT05612100
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Electronic Health Record Review, Questionnaire Administration, Survey Administration
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
23
States / cities
Albert Lea, Minnesota • Baxter, Minnesota • Bemidji, Minnesota + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 23, 2026, 12:57 PM EDT
Recruiting Not applicable Interventional

Impact of Ketogenic Diet on Tumor Microenvironment in Patients With Breast Cancer

NCT07574671
View directory record Official record
Conditions
Breast Cancer
Interventions
Ketogenic diet
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 23, 2026, 12:57 PM EDT
Completed Not applicable Interventional

Soy-Based Meal Replacement in Helping Women With Stage I, Stage II, or Stage III Breast Cancer in Complete Remission Lose Weight

NCT00343434
View directory record Official record
Conditions
Breast Cancer, Obesity
Interventions
behavioral dietary intervention, exercise intervention, soy isoflavones, soy protein isolate, counseling intervention, educational intervention, psychosocial assessment and care, quality-of-life assessment
Behavioral · Dietary Supplement · Other + 1 more
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 23, 2026, 12:57 PM EDT
Completed Not applicable Interventional

Purpose Project: Reclaiming Life Purpose After Breast Cancer (Feasibility Study)

NCT03233334
View directory record Official record
Conditions
Breast Cancer
Interventions
Purpose Project
Behavioral
Lead sponsor
Allina Health System
Other
Eligibility
25 Years to 74 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 23, 2026, 12:57 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

NCT06330064
View directory record Official record
Conditions
Recurrent or Metastatic Solid Tumors
Interventions
Ifinatamab deruxtecan
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Los Angeles, California • Whittier, California • Skokie, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 23, 2026, 12:57 PM EDT
Withdrawn Phase 2 Interventional

To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer

NCT05212701
View directory record Official record
Conditions
Fatigue, Locally Advanced or Metastatic Breast Cancer
Interventions
Reparixin, Placebo
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Cary, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 23, 2026, 12:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer

NCT02448771
View directory record Official record
Conditions
Breast Cancer Stage IV, Unresectable Locally Advanced Invasive Breast Cancer, Metastatic Invasive Breast Cancer
Interventions
Palbociclib, Bazedoxifene
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Oct 23, 2026, 12:57 PM EDT
Completed Phase 1 Interventional

Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer

NCT00174434
View directory record Official record
Conditions
Breast Neoplasms
Interventions
SU011248, Paclitaxel
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
6
States / cities
Harvey, Illinois • Indianapolis, Indiana • Munster, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2009 · Synced Oct 23, 2026, 12:57 PM EDT
Completed Phase 2 Interventional Results available

BKM120 For Triple Negative Breast Cancer

NCT01790932
View directory record Official record
Conditions
Breast Cancer
Interventions
BKM120
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 23, 2026, 12:57 PM EDT
Completed Phase 1 Interventional

Exploratory Study of Safety and ex Vivo Fluorescence of BLZ-100 in Adult Subjects With Solid Tumors Undergoing Surgery

NCT02496065
View directory record Official record
Conditions
Tumors, Breast
Interventions
BLZ-100
Drug
Lead sponsor
Blaze Bioscience Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Bellevue, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 23, 2026, 12:57 PM EDT
Completed No phase listed Observational

Regional Anesthesia Versus General Anesthesia on Circulating Tumor Cells (CTC)

NCT01716065
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Defense and Veterans Center for Integrative Pain Management
Other
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2014 · Synced Oct 23, 2026, 12:57 PM EDT
Withdrawn No phase listed Observational

Ductal Lavage in Assessing Women With Early Breast Cancer or at High Risk of Developing Breast Cancer and Who Are Eligible For Tamoxifen Therapy

NCT00083044
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 64 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
2
States / cities
Birmingham, Alabama • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 25, 2012 · Synced Oct 23, 2026, 12:57 PM EDT
Completed No phase listed Observational

Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant

NCT07008963
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
non-interventional
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Redwood Shores, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 23, 2026, 12:57 PM EDT
Completed Not applicable Interventional

Preventing Persistent Pain and Reducing Depressive and Anxious Symptoms Following Mastectomy and Lumpectomy

NCT03430765
View directory record Official record
Conditions
Persistent Postsurgical Pain, Breast Cancer Female, Ductal Carcinoma in Situ
Interventions
Acceptance and Commitment Therapy
Behavioral
Lead sponsor
Katherine Hadlandsmyth
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Oct 23, 2026, 12:57 PM EDT
Recruiting Not applicable Interventional

Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing

NCT04968964
View directory record Official record
Conditions
Breast Cancer, Cancer of the Breast
Interventions
DiviTum® TKa assay, Study Care Plans
Device · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 23, 2026, 12:57 PM EDT
Completed Not applicable Interventional Results available

Efficacy of Gamma Camera Used Intraoperatively for ID of Sentinel Lymph Nodes w/ Lymphoscintigraphy

NCT01314963
View directory record Official record
Conditions
Multiple Myeloma, Breast Cancer
Interventions
Prototype intraoperative handheld gamma camera (pIHGC), Lymphoscintigraphy with intraoperative gamma probes (GP), radioactive Tc99M
Device · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Oct 23, 2026, 12:57 PM EDT
Completed Not applicable Interventional

Prevention of Lymphedema Among Breast Cancer Patients Through Implementation of an Integrative Therapy Program (ITP)

NCT02528539
View directory record Official record
Conditions
Lymphedema
Interventions
ITP
Other
Lead sponsor
Huntington Memorial Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 23, 2026, 12:57 PM EDT
Recruiting Phase 2 Interventional

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

NCT05564377
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
Interventions
Alpelisib, Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Echocardiography Test, Fluorouracil, Fulvestrant, Ipatasertib, Leucovorin, Magnetic Resonance Imaging, Multigated Acquisition Scan, Mutation Carrier Screening, Neratinib Maleate, Nilotinib Hydrochloride Monohydrate, Olaparib, Oxaliplatin, Paclitaxel, Palbociclib, Panitumumab, Positron Emission Tomography, Selumetinib Sulfate, Sotorasib
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
2,900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
479
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 355 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 23, 2026, 12:57 PM EDT
Completed Phase 1 Interventional

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

NCT04584112
View directory record Official record
Conditions
Triple-Negative Breast Cancer
Interventions
Tiragolumab, Atezolizumab, Nab-paclitaxel, Carboplatin, Doxorubicin, Cyclophosphamide, Granulocyte colony-stimulating factor (G-CSF), Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Birmingham, Alabama • Chicago, Illinois • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 23, 2026, 12:57 PM EDT
Terminated Phase 2 Interventional Results available

Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer

NCT01745367
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Tivozanib Hydrochloride, paclitaxel, Placebo
Drug
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
20
States / cities
Birmingham, Alabama • Jacksonville, Florida • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 23, 2026, 12:57 PM EDT